Lichen Planus Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Lichen Planus Industry Market Size Be by 2025?
The lichen planus market has seen a robust increase in size over the past few years. The market, which is set to rise from $1.18 billion in 2024 to $1.26 billion in 2025, will see a compound annual growth rate (CAGR) of 7.0%. The historical growth of this market is due to factors such as enhanced understanding of skin conditions, better healare accessibility, an increasing aged population, growth of dermatology clinics, and a rise in healare expenditure.

What's the Long-Term Growth Forecast for the Lichen Planus Market Size Through 2029?
The future predicts a robust growth for the lichen planus market, with a projected value of $1.65 billion by 2029, corresponding to a compound annual growth rate (CAGR) of 6.9%. This growth for the forecasted period is likely to stem from several factors such as soaring demand for biologic treatments, continuous clinical trials seeking innovative solutions, progression in teledermatology facilities, an augmented emphasis on individualized medicine, and the development of healare infrastructure in nascent markets. The forecast period is also set to witness noteworthy trends such as the creation of specific biologics, the application of artificial intelligence in diagnosing skin conditions, breakthroughs in drug delivery techniques, the incorporation of telemedicine technologies, utilization of wearable devices to monitor skin health, and the advent of 3D skin imagery technology.

View the full report here:
https://www.thebusinessresearchcompany.com/report/lichen-planus-global-market-report

What Are the Key Growth Drivers Fueling the Lichen Planus Market Expansion?
The escalating occurrence of autoimmune diseases is projected to drive the expansion of the lichen planus market in the future. In autoimmune diseases, the immune system erroneously targets the body's own healthy cells, including diseases like rheumatoid arthritis, lupus, type 1 diabetes, multiple sclerosis, and psoriasis. The increased frequency of these diseases can be attributed to genetic predisposition, as particular gene variations can impact immune system activity and cause abnormalities in connective tissue. The rise in autoimmune diseases not only represents a broader imbalance in immune regulation, but also leads to a higher number of lichen planus cases. For example, in June 2024, data from the Australian Institute of Health and Welfare, a government agency based in Australia, showed that roughly 514,000 people (2.0%) were afflicted with rheumatoid arthritis in 2022. This accounted for 2.0% of the total disease load and 16% of the musculoskeletal conditions load in 2023, with 1,322 deaths (5.1 deaths per 100,000 population) logged in 2022, equating to 0.7% of all deaths. Thus, the amplifying prevalence of autoimmune diseases is fuelling the growth of the lichen planus market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24279&type=smp

What Are the Key Trends Driving Lichen Planus Market Growth?
Major leaders in the lichen planus industry are focusing on the creation of novel solutions like liposomal formulations to enhance targeted drug delivery and minimize systemic side effects. These liposomal formulations are a type of drug delivery system wherein active ingredients are encased within liposomes-tiny vesicles composed of lipid bilayers. This not only improves the stability of the drug, facilitates its absorption, but also enables targeted delivery while reducing systemic side effects. For example, Lipella Pharmaceuticals Inc., an American biotech firm specializing in developing treatments for severe diseases, has received clearance from the US Food and Drug Administration in February 2025 for an expanded access program (EAP) for their product, LP-310. LP-310 is a liposomal formulation of tacrolimus that is created to offer targeted relief to patients suffering from oral lichen planus (OLP), while keeping systemic exposure to a minimum. This program provides access to treatments for patients with serious or terminal conditions, who have unmet medical requirements, outside of clinical trials before they gain full approval.

How Is the Lichen Planus Market Segmented?
The lichen planus market covered in this report is segmented -

1) By Disease Type: Lichen Planus, Oral Lichen Planus, Genital Lichen Planus, Lichen Planus Pigmentosus
2) By Treatment Type: Topical Therapies, Systemic Therapies, Phototherapy, Alternative Treatment
3) By Route Of Administration: Topical, Oral, Intravenous, Intradermal
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Lichen Planus: Papular Lichen Planus, Hypertrophic Lichen Planus, Actinic Lichen Planus, Linear Lichen Planus, Annular Lichen Planus
2) By Oral Lichen Planus: Reticular Oral Lichen Planus, Erosive Oral Lichen Planus, Atrophic Oral Lichen Planus, Plaque-Like Oral Lichen Planus, Bullous Oral Lichen Planus
3) By Genital Lichen Planus: Erosive Genital Lichen Planus, Papular Genital Lichen Planus, Annular Genital Lichen Planus, Vulvovaginal-Gingival Syndrome
4) By Lichen Planus Pigmentosus: Diffuse Lichen Planus Pigmentosus, Blotchy Lichen Planus Pigmentosus, Linear Lichen Planus Pigmentosus, Perifollicular Lichen Planus Pigmentosus, Flexural Lichen Planus Pigmentosus

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24279&type=smp

Which Companies Are Leading the Charge in Lichen Planus Market Innovation?
Major companies operating in the lichen planus market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals plc, LEO Pharma A/S, Basilea Pharmaceutica Ltd., UCB S.A., Almirall SA, Lipella Pharmaceuticals Inc.

Which Regions Are Leading the Global Lichen Planus Market in Revenue?
North America was the largest region in the lichen planus market in 2024. The regions covered in the lichen planus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24279

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.